WAY stock forecast, quote, news & analysis
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations... Show more
Why Waystar Holding (WAY) Stock Is Up +12% in the Last 30 Days
Key Takeaways
- Waystar Holding (WAY) gained roughly 12% over the last 30 days, climbing from about $25.66 in mid-September to around $28.81.
- The advance extends a broader multi-month recovery built on second-quarter 2026 results, which showed 18% year-over-year revenue growth and raised full-year guidance.
- AI-powered revenue cycle management and the AltitudeAI platform remain central to the company's growth story and investor sentiment.
- Over the last quarter, the stock rose approximately 24% from its late-July levels, even after a sharp post-earnings pullback.
- Investors are now watching upcoming quarterly results, subscription-revenue momentum, and continued guidance execution.
Waystar Holding (WAY) Company Overview and Market Position
Waystar Holding Corp. provides mission-critical, cloud-based software that simplifies healthcare payments for providers across the continuum of care. The company's platform streamlines revenue cycle workflows such as eligibility checks, prior authorization, claims submission and monitoring, denial management, and patient payment collection. Waystar serves more than 30,000 clients representing over one million distinct providers, including 16 of the top 20 institutions on the U.S. News Best Hospitals list, and processes over 7.5 billion healthcare payment transactions annually.
Waystar differentiates itself through its proprietary data asset and AI capabilities, most notably its AltitudeAI suite, which automates denial prevention and appeals while improving claim accuracy. The company generates the large majority of its revenue through recurring subscriptions and volume-based fees, giving it high visibility into future results. Following its 2024 initial public offering and the late-2025 acquisition of Iodine Software, Waystar has positioned itself as a consolidator in AI-driven revenue cycle management.
Waystar Holding (WAY) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, WAY advanced from a closing level of approximately $25.66 in mid-September to around $28.81, a gain of roughly 12%. The move was not linear: shares dipped to about $24.64 in late September before staging a steady rally through October that carried the stock to its recent highs.
The last quarter tells a broader story. From late July, when shares traded near $23.13, the stock has risen approximately 24%. That climb occurred despite a sharp post-earnings selloff at the end of July, when the shares fell from about $24.52 to $20.94 in a single session. The subsequent recovery through August, September, and October reflects investors gradually regaining confidence in the company's growth trajectory and AI-driven positioning.
What Drove WAY Stock Price in the Last 30 Days
The most recent 30-day advance built on catalysts established earlier in the quarter rather than a single discrete event. Sentiment has been supported by Waystar's second-quarter 2026 results, reported in late July, which showed revenue of $319.7 million, up 18% year over year, and adjusted EBITDA of $136.7 million at a 43% margin. Management also raised full-year 2026 guidance to a revenue range of $1.276 billion to $1.294 billion and an adjusted EBITDA range of $535 million to $545 million.
Analyst commentary has reinforced the positive tone. Following the earnings release, several firms reiterated constructive views, including Buy ratings from BMO Capital, Needham, RBC Capital, and Bank of America Securities, with price targets ranging up to $38. The company's recognition on the Time 100 Most Influential Companies list and its Time Impact in AI award provided additional external validation of its AI strategy.
Broader sector dynamics also played a role, as investor interest in AI-enabled healthcare and enterprise software continued to support valuation multiples across the group. The October rally appears to reflect sustained momentum in the AI-driven healthcare payments theme, with improving technical sentiment carrying the shares to multi-month highs.
What Drove WAY Stock Performance Over the Last Quarter
The quarterly trend was shaped primarily by Waystar's fundamental execution and its evolving AI narrative. Second-quarter results demonstrated accelerating subscription revenue growth of 34% year over year, while the number of clients generating more than $100,000 in trailing twelve-month revenue rose 15% to 1,453. Net revenue retention held at 108%, within the company's historical range.
The quarter also featured a leadership transition, with the appointment of Alpana Wegner as Chief Financial Officer, and continued progress integrating Iodine Software, which produced more than $6 million in bookings from existing Waystar clients. These developments reinforced the platform-consolidation thesis, as healthcare providers increasingly shift from fragmented point solutions toward a single connected software platform.
At the same time, the late-July earnings selloff highlighted investor sensitivity to details such as a modest EPS miss versus consensus and slower volume-based revenue growth of 3%. The stock's recovery since then reflects a market more focused on durable subscription growth, margin expansion, and AI adoption than on near-term volume fluctuations.
Trending AI Robots
For traders seeking a systematic approach to stocks like WAY, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These robots vary in strategy, timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum to longer-term trend following. The page is designed to help investors evaluate how automated, data-driven systems are interpreting current market conditions and identify strategies aligned with their own objectives.
WAY Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to influence WAY's trajectory. The next quarterly earnings release will be a key checkpoint, with investors focused on whether subscription revenue growth remains robust, net revenue retention stays within its historical range, and adjusted EBITDA margins continue to expand. Execution on the raised full-year guidance and further adoption of AltitudeAI and Iodine capabilities will also be closely monitored.
Macroeconomic and regulatory developments in healthcare, including changes in Medicaid coverage and uninsured populations, could affect transaction volumes and provider demand. Competitive pressures in the revenue cycle management space and the pace of enterprise AI adoption represent additional variables. Investors may also watch institutional positioning and analyst estimate revisions for signals on how the growth narrative is evolving.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for WAY shows an upward move is likely
WAY's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 79 similar instances where the Aroon Indicator showed a similar pattern. In 69 of the 79 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAY advanced for three days, in 110 of 139 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for WAY moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In 11 of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WAY as a result. In 28 of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for WAY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 25 similar instances when the indicator turned negative. In 16 of the 25 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
WAY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. WAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.364) is normal, around the industry mean (4.477). P/E Ratio (39.930) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (6.065).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry